Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ANRO vs ITRM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–1 Matrix Metrics)

ANRO Overall Winner 6-Pillar Tally: ANRO 3 – 2 ITRM (1 Tie) Matrix Metrics: ANRO 6 – 1 ITRM

As of Nov 20, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ANRO carries a Unified Composite Score of 45.8/100 (HOLD) at $25.37 (N/M Forward P/E, 0.0% operating margin), whereas ITRM carries 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin).

  • Composite vs. Pillar Nuance: While ITRM currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. ANRO 45.8/100 HOLD), ANRO captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1982.3% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: ANRO is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.5); meanwhile ITRM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANRO vs ITRM
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.37
-4.3% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.86β · 91% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.9%) with fading momentum, RSI 49
RSI-14: 48.5 · SMA20: $25.37 · SMA50: $25.58
ITRM NASDAQ
Iterum Therapeutics plc Ordinary Share
Pharmaceutical Preparations
$0.03
-57.39% 1D
Market Cap $3.8M
TTM Revenue $390,000
Forward P/E N/M
Beta / 30D Vol 1.61β · 508% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 75.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.9%), weak momentum, RSI 26
RSI-14: 25.9 · SMA20: $0.15 · SMA50: $0.23

6-Pillar Scorecard Institutional Category Breakdown (ANRO 3 – 2 ITRM)

Columns: Metric · ANRO · ITRM
1. Valuation Multiples ITRM
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 9.6x
2. Growth & Scale ANRO
Revenue Growth (YoY) +0.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $390,000
Market Cap $1.1B $3.8M
3. Profitability & Quality ANRO
Gross Margin N/A 29.7%
Operating Margin 0.0% -1982.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -46.7% -555.7%
4. Balance Sheet & Cash Flow ANRO
Cash Generation (TTM) -$80M -$19M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $301M Net Cash -555.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ITRM
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 80.4% (8th %ile) N/A (N/A)
Put/Call OI Skew 20.60x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANRO (6) vs ITRM (1)
Institutional Metric ANRO ITRM Criterion Row Edge
Market Capitalization
Scale
$1.1B $3.8M Larger Scale ANRO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -100.0% Higher Growth ANRO
Operating Margin (TTM)
Profitability
0.0% -1982.3% Higher Margin ANRO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-46.7% -555.7% Higher ROE ANRO
52-Week Range Position
Momentum
52% ($13–$37) 0% ($0–$1) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
1.86β · 91% Vol 1.61β · 508% Vol Lower Realized Risk ANRO
Unified Institutional Score
Composite Signal
45.8 / 100 (HOLD) 50.5 / 100 (HOLD) Higher Composite ITRM
Trailing 12M Revenue (USD)
Operating Scale
N/A $390,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 29.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 9.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$80M ($301M Net Cash) -$19M EBITDA (-555.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +98.35 pp
ANRO: +8.97% · ITRM: -89.38%
3M Horizon ANRO +110.68 pp
ANRO: +21.06% · ITRM: -89.62%
6M Horizon ANRO +136.87 pp
ANRO: +44.66% · ITRM: -92.21%
1Y Horizon ANRO +136.87 pp
ANRO: +44.66% · ITRM: -92.21%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs ITRM. Trailing 12-month operating profitability (ANRO 0.0% vs ITRM -1982.3%) and valuation multiples (ANRO N/M vs ITRM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M
ITRM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$390,000
Gross Margin29.7%
Op. Margin-1982.3%
ROE / Fwd P/E-555.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANRO BREAKDOWN
61d in phase · OBV DISTRIBUTION
Current IV 80.4%
IV Percentile 8th %ile
Put/Call OI Skew 20.60x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ITRM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ITRM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ITRM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8M market capitalization and -1982.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANRO vs ITRM Key Questions & Quantitative Answers

As of Nov 20, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ANRO carries a Unified Composite Score of 45.8/100 (HOLD) at $25.37 (N/M Forward P/E, 0.0% operating margin), whereas ITRM carries 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin). Composite vs. Pillar Nuance: While ITRM currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. ANRO 45.8/100 HOLD), ANRO captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1982.3% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY). Technical & Structure Timing Caution: ANRO is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.5); meanwhile ITRM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANRO leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ITRM at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $390,000 TTM revenue (29.7% gross margin, -1982.3% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus $390,000 for ITRM. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ITRM.

ITRM screens cheaper on headline valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ITRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus ITRM (-555.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ANRO carries 80.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 20.60x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.86β · 91% Vol realized risk). By comparison, ITRM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 508% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.